Dose adjustments of afatinib among patients with advanced non-small cell lung cancer (NSCLC) appear to reduce the incidence and severity of treatment-related adverse events without negatively affecting efficacy, according to a post-hoc analysis of the LUX-Lung 3 and LUX-Lung 6 trials.1

Dose reductions, which occurred mostly within the first 6 months of treatment, were associated with decreases in the incidence and severity of treatment-related adverse events.

Median progression-free survival was similar between those who had a dose reduction within the first 6 months and those who did not.

Continue Reading

These findings may provide clinicians and patients with confidence when reducing the dose of afatinib to address treatment-related adverse events.

The multicenter, open-label, phase 3 LUX-Lung 3 and LUX-Lung 6 trials evaluated the efficacy and safety of first-line afatinib, compared with that of chemotherapy, among patients with EGFR mutation-positive, advanced NSCLC.

RELATED: Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer?

Both studies demonstrated a significant improvement in progression-free survival, lung cancer-related symptoms, and quality of life with afatinib.


  1. New analysis showed dose adjustment of Giotrif (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer [press release]. Boehringer Ingelheim website. Updated September 8, 2016. Accessed September 9, 2016.